LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial

Jason J. Luke, Piotr Rutkowski, Paola Queirolo, M. Del Vecchio, Jacek Mackiewicz, V. Chiarion Sileni, Luis de la Cruz‐Merino, Muhammad A. Khattak, Dirk Schadendorf, Georgina V. Long, Paolo A. Ascierto, Mario Mandalà, Federica De Galitiis, Sondak Vk, Richard A. Scolyer, John M. Kirkwood, K. Chen, Nageatte Ibrahim, S. Ahsan, Alexander M.M. Eggermont